Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction - Trial NCT05637853

Timeline & Enrollment

Primary Outcome

Safety and feasibility of fast telemonitored sequencing of heart failure medications in HFrEF patients

Summary

Research hypothesis:
 
 Fast telemonitored medical sequencing in patients with heart failure with reduced ejection
 fraction (HFrEF) is safe and feasible.
 
 Background:
 
 Modern therapy for HFrEF offers a highly effective arsenal of drugs, devices and
 interventional therapies, yet mortality and morbidity remain high in the cohort. One major
 problem is that drug therapy introduction and up titration has been very hard to implement in
 a majority of HFrEF patients. Most previous telemonitoring studies have focused on the
 continuous monitoring of patients and the monitoring itself has been the main intervention. A
 potentially more effective way to use telemonitoring in heart failure patients may be to
 combine the technique with a medical intervention when the patients are most vulnerable to
 heart failure events. The best therapeutic window lies in the period after newly diagnosed
 heart failure or right after a recent hospitalization following worsened chronic HFrEF.
 
 Method:
 
 We aim to use telemonitoring for fast sequencing of heart failure drugs for patients with
 HFrEF.

ICD-10 Classifications